Cargando…

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

Poly (ADP-ribose) polymerase inhibitors (PARPis) are becoming increasingly meaningful in oncology, and their therapeutic drug monitoring (TDM) might be beneficial for patients. Several bioanalytical methods have been reported for PARPis quantification in human plasma, but advantages might be obtaine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canil, Giovanni, Orleni, Marco, Posocco, Bianca, Gagno, Sara, Bignucolo, Alessia, Montico, Marcella, Roncato, Rossana, Corsetti, Serena, Bartoletti, Michele, Toffoli, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221204/ https://www.ncbi.nlm.nih.gov/pubmed/37242766 http://dx.doi.org/10.3390/pharmaceutics15051524

Ejemplares similares

A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring
por: Zanchetta, Martina, et al.
Publicado: (2021)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients
por: Iacuzzi, Valentina, et al.
Publicado: (2019)

Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring
por: Orleni, Marco, et al.
Publicado: (2023)

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
por: Posocco, Bianca, et al.
Publicado: (2020)

The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure
por: Gagno, Sara, et al.
Publicado: (2023)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
por: Guy, Holly, et al.
Publicado: (2018)

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
por: Wallace, Katrine, et al.
Publicado: (2019)

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
por: Roncato, Rossana, et al.
Publicado: (2022)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS
por: Ottria, Roberta, et al.
Publicado: (2019)

Development and validation of Lenalidomide in human plasma by LC-MS/MS
por: Ranganathan, Premanand, et al.
Publicado: (2019)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
por: Dalle Fratte, Chiara, et al.
Publicado: (2023)

Development and validation of an LC-MS/MS method for tyrphostin A9
por: Meyer, Lyndsey F., et al.
Publicado: (2019)

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
por: Attwa, Mohamed W, et al.
Publicado: (2020)

Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma
por: Millet, Aurélien, et al.
Publicado: (2021)

Development and validation of a LC–MS/MS method for quantification of hetrombopag for pharmacokinetics study
por: Chen, Tao, et al.
Publicado: (2015)

Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability
por: Kadi, Adnan A., et al.
Publicado: (2016)

Evaluation of Stability of Thiopurine Metabolites Using a Validated LC-MS/MS Method
por: Yoo, In-Young, et al.
Publicado: (2018)

Development and validation of an LC–MS/MS method for the determination of biogenic amines in wines and beers
por: Nalazek-Rudnicka, Katarzyna, et al.
Publicado: (2017)

Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma
por: Attwa, Mohamed W., et al.
Publicado: (2018)

Development and validation of an LC–MS/MS method for the quantification of artificial sweeteners in human matrices
por: Greibe, Eva, et al.
Publicado: (2022)

Development and Validation of LC-MS/MS Method for Determination of Cytisine in Human Serum and Saliva
por: Wróblewski, Karol, et al.
Publicado: (2023)

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
por: Morosi, Lavinia, et al.
Publicado: (2020)

A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid
por: Sidhu, Rohini, et al.
Publicado: (2015)

LC-MS/MS Validation Analysis of Trastuzumab Using dSIL Approach for Evaluating Pharmacokinetics
por: Budhraja, Rohit H., et al.
Publicado: (2016)

Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
por: Schokker, Sandor, et al.
Publicado: (2020)

Development and Validation of LC-MS/MS for Analyzing Potential Genotoxic Impurities in Pantoprazole Starting Materials
por: Chen, Yuyuan, et al.
Publicado: (2020)

Development and Validation of an LC-MS/MS Method for the Ultra-Trace Analysis of Pacific Ciguatoxins in Fish
por: Nagae, Mika, et al.
Publicado: (2021)

Development and validation of a novel LC-MS/MS assay for C-peptide in human serum
por: Owusu, Benjamin Y., et al.
Publicado: (2020)

Validation of an LC-MS/MS method for the quantitation of phytosterols derived from Aloe vera gel
por: Nabeshima, Kazumi, et al.
Publicado: (2022)

An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS
por: Self, Wade, et al.
Publicado: (2022)

Development and validation of an LC-MS/MS method by one-step precipitation for cinacalcet in human plasma
por: Lu, Haoyang, et al.
Publicado: (2023)

A Validated LC-MS/MS Method for Performing Belatacept Drug Monitoring in Renal Transplantation
por: Chhun, Stéphanie, et al.
Publicado: (2023)

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
por: Bignucolo, Alessia, et al.
Publicado: (2017)

Method validation studies and an inter-laboratory cross validation study of lenvatinib assay in human plasma using LC-MS/MS
por: Mano, Yuji
Publicado: (2018)

Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA
por: Buchwald, Armin, et al.
Publicado: (2012)

Development and validation of an LC-MS/MS method for determination of compound K in human plasma and clinical application
por: Kim, Jung Soo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tisfjh56vui62d7rsnmt8oc81v